2016•International Journal of Academic MedicineRequires access

Prescription patterns and cost of illness in asthma and chronic obstructive pulmonary disease patients

S. Asad Ali, Aleemuddin Naveed, Abida Perveen, Shazia Yousuf, Amena Ahmed, Mir Asad Ali Hashmi, Yaseen Gigani

Open publisher page 1 citations

Abstract

Background: Although economic burden data of chronic obstructive pulmonary disease (COPD) and asthma for various countries are available, data among Indian population are unavailable. Thus, the aim of this study was to measure the prescription pattern and cost of illness (COI) of asthma and COPD patients. Methods: This prospective, observational, bottom-up study collected economic, diagnostic, and therapeutic data from 150 COPD and asthma patients. The study was carried out for an 8-month period at Princess Esra Hospital, a Unit of Owaisi Group of Hospitals, located at Shalibanda, Hyderabad, Telangana, India. Results: Societal perspective was used to account for both direct and indirect costs. Asthma and COPD account for Rs. 12,852 and Rs. 16,514 in annual direct costs per patient per year. Inpatient cost was considerably higher than the outpatient cost. Hospitalization costs ranked first in direct costs followed by laboratory examination and medication costs. Average annual total direct cost per patient for COPD (Rs. 5000–25,000) was considerably higher than asthma (Rs. 1000–20,000). Antibiotics, mucolytics, short-acting beta-2 agonists, long-acting beta-2 agonists, long-acting muscarinic antagonists, leukotriene receptor antagonists, corticosteroids, antihistamines, and methylxanthines were the common categories of drugs prescribed for the two disorders. Conclusion: In summary, we found that COI for asthma and COPD are substantial. Hospitalization and medication costs can be reduced by implementing preventive strategies including but not limited to home care services, rehabilitation therapies, smoking cessation programs, medication assessment, and patient compliance programs. Future researchers should examine the treatment strategies and interventions that may help to reduce the burden of COPD and asthma. The following core competencies are addressed in this article: Patient care, practice-based learning and improvement, systems-based practice.

About this research paper

What this paper is about

Background: Although economic burden data of chronic obstructive pulmonary disease (COPD) and asthma for various countries are available, data among Indian population are unavailable. Thus, the aim of this study was to measure the prescription pattern and cost of illness (COI) of asthma and COPD patients. Methods: This prospective, observational, bottom-up study collected economic, diagnostic, and therapeutic data from 150 COPD and asthma patients. The study was carried out for an 8-month period at Princess Esra Hospital, a Unit of Owaisi Group of Hospitals, located at Shalibanda, Hyderabad, Telangana, India. Results: Societal perspective was used to account for both direct and indirect costs. Asthma and COPD account for Rs. 12,852 and Rs. 16,514 in annual direct costs per patient per year. Inpatient cost was considerably higher than the outpatient cost. Hospitalization costs ranked first in direct costs followed by laboratory examination and medication costs. Average annual total direct cost per patient for COPD (Rs. 5000–25,000) was considerably higher than asthma (Rs. 1000–20,000). Antibiotics, mucolytics, short-acting beta-2 agonists, long-acting beta-2 agonists, long-acting muscarinic antagonists, leukotriene receptor antagonists, corticosteroids, antihistamines, and methylxanthines were the common categories of drugs prescribed for the two disorders. Conclusion: In summary, we found that COI for asthma and COPD are substantial. Hospitalization and medication costs can be reduced by implementing preventive strategies including but not limited to home care services, rehabilitation therapies, smoking cessation programs, medication assessment, and patient compliance programs. Future researchers should examine the treatment strategies and interventions that may help to reduce the burden of COPD and asthma. The following core competencies are addressed in this article: Patient care, practice-based learning and improvement, systems-based practice.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background: Although economic burden data of chronic obstructive pulmonary disease (COPD) and asthma for various countries are available, data among Indian population are unavailable. Thus, the aim of this study was to measure the prescription pattern and cost of illness (COI) of asthma and COPD patients. Methods: This prospective, observational, bottom-up study collected economic, diagnostic, and therapeutic data from 150 COPD and asthma patients. The study was carried out for an 8-month period at Princess Esra Hospital, a Unit of Owaisi Group of Hospitals, located at Shalibanda, Hyderabad, Telangana, India. Results: Societal perspective was used to account for both direct and indirect costs. Asthma and COPD account for Rs. 12,852 and Rs. 16,514 in annual direct costs per patient per year. Inpatient cost was considerably higher than the outpatient cost. Hospitalization costs ranked first in direct costs followed by laboratory examination and medication costs. Average annual total direct cost per patient for COPD (Rs. 5000–25,000) was considerably higher than asthma (Rs. 1000–20,000). Antibiotics, mucolytics, short-acting beta-2 agonists, long-acting beta-2 agonists, long-acting muscarinic antagonists, leukotriene receptor antagonists, corticosteroids, antihistamines, and methylxanthines were the common categories of drugs prescribed for the two disorders. Conclusion: In summary, we found that COI for asthma and COPD are substantial. Hospitalization and medication costs can be reduced by implementing preventive strategies including but not limited to home care services, rehabilitation therapies, smoking cessation programs, medication assessment, and patient compliance programs. Future researchers should examine the treatment strategies and interventions that may help to reduce the burden of COPD and asthma. The following core competencies are addressed in this article: Patient care, practice-based learning and improvement, systems-based practice.

Key concepts: Medicine, Asthma, COPD, Medical prescription, Indirect costs, Psychological intervention, Observational study, Population

Related papers

Back to paper searchBrowse research topicsOriginal source
Prescription patterns and cost of illness in asthma and chronic obstructive pulmonary disease patients — Research Paper | ScholarLens